ELAN FIT ELAN UNFIT
Lancet Healthy Longev. 2024 Mar;5(3):e182-e193
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial
Joël Guigay, Cécile Ortholan, Damien Vansteene, Didier Cupissol, Caroline Even, Marie-Christine Kaminsky, Christian Sire, Emmanuel Blot, Philippe Debourdeau, Laurence Bozec, Esma Saada-Bouzid, Jérôme Fayette, Pierre Dalloz, Yoann Pointreau, Hervé Le Caer, Claire Falandry, Laurence Digue, Antoine Braccini, Stéphane Lopez, Pierre Guillet, Cécile Michel, Nadir Cheurfa, Dominique Schwob, Jean Bourhis, Cécile Mertens, Anne Aupérin; ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups and the GORTEC